Showing 3721-3730 of 5092 results for "".
- Biosimilar Update: Fresenius Kabi’s Idacio Joins Growing List of Available Humira Biosimilarshttps://practicaldermatology.com/news/biosimilar-update-fresenius-kabis-idacio-joins-growing-list-of-available-humira-biosimilars/2461836/Fresenius Kabi’s citrate-free adalimumab biosimilar
- Sirnaomics Gets FDA Go Ahead to Move STP705 Into Late-Stage Clinical Development for isSCChttps://practicaldermatology.com/news/sirnaomics-gets-fda-go-ahead-to-move-stp705-into-late-stage-clinical-development-for-isscc/2461788/Sirnaomics Ltd.’s STP705 for the treatment of Squamous Cell Carcinoma in situ (isSCC) is moving into late-stage clinical development after encouraging Phase IIa and Phase IIb clinical results. These results were shared with the U.S. Food and Drug Administration (FDA) in an En
- Castle Biosciences Gives Back for Skin Cancer Awareness Monthhttps://practicaldermatology.com/news/castle-biosciences-gives-back-for-skin-cancer-awareness-month/2461750/Castle Biosciences, Inc. is teaming up with The Sun Bus and The Skin Cancer Foundation to support skin cancer prevention, research, education and advocacy. “At our core, we are passionate about transforming disease management, improving health and making a meaningful difference in
- It's Going to Be a Scorcher: Experts Predict Extreme UV Index Ratings This Memorial Dayhttps://practicaldermatology.com/news/its-going-to-be-a-scorcher-experts-predict-extreme-uv-index-ratings-this-memorial-day/2461739/A dozen U.S. cities are expected to have extreme ultraviolet (UV) index ratings (10+) this Memorial Day and throughout the summer, according to data from the
- And the Winners Are...Mary Kay, ESDR Announce New Grant Recipientshttps://practicaldermatology.com/news/and-the-winners-are-mary-kay-esdr-announce-new-grant-recipients/2461724/Mary Kay Inc. and
- FDA Greenlights Phio Pharmaceuticals' Trial of PH-762 in Skin Cancerhttps://practicaldermatology.com/news/fda-greenlights-phio-pharmaceuticals-trial-of-ph-762-in-skin-cancer/2461721/The U.S. Food and Drug Administration (FDA) has cleared Phio Pharmaceuticals’ Investigational New Drug (IND) application to move ahead with a clinical trial of PH-762 for treating skin cancer. PH-762 is an INTASYL compound
- MRA Announces $6.3 Million in Grants to Advance Melanoma Preventionhttps://practicaldermatology.com/news/mra-announces-63-million-in-grants-to-advance-melanoma-prevention/2461691/The Melanoma Research Alliance (MRA) announced a new $6.3 million commitment to fund melanoma resear
- Galderma's Sculptra Now FDA Approved for Cheek Wrinkleshttps://practicaldermatology.com/news/galdermas-sculptra-now-fda-approved-for-cheeks/2461683/The U.S. Food and Drug Administration (FDA) has approved Sculptra (injectable poly-L-lactic acid (PLLA-SCA)) for the correction of fine lines and wrinkles in the cheek area. Sculptra is the first FDA-approved PLLA collagen stimulator that helps stimulate natural collagen production in the
- La Roche-Posay Gives Back: Brand Offers Free Public Screenings in NYChttps://practicaldermatology.com/news/la-roche-posay-gives-back-brand-offers-free-public-screenings-in-nyc/2461678/La Roche-Posay is kicking off Melanoma Awareness Month with free public skin cancer screenings at Hudson Yards on Sunday, April 30th and Monday, May 1st. On Sunday, April 30th and Monday, May 1st (Melanoma Monday,) La Roche-Posay, in partners
- Rodan + Fields Gives Back: Company Joins The Recycling Partnershiphttps://practicaldermatology.com/news/rodan-fields-gives-back-company-joins-the-recycling-partnership/2461673/Rodan + Fields, LLC. is joining 80 leading companies to support The Recycling Partnership, a nonprofit organization committed to building a better recycling system. Investing in The Recycling Partnership will help strengthen recycling access, education and infrastructure, advance